C-CAMP start-up Bugworks to collaborate with GARD-P to co-develop novel broad-spectrum antibiotic

Published - June 13, 2024 09:00 am IST - Bengaluru

Among these pathogens are WHO critical priority pathogens, carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae.

Among these pathogens are WHO critical priority pathogens, carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. | Photo Credit: dra_schwartz

Bugworks Research Inc. (Bugworks), a Centre for Cellular and Molecular Platforms (C-CAMP) incubated start-up along with Global Antibiotic Research and Development Partnership (GARDP) has announced a collaboration agreement to co-develop an innovative compound (BWC0977) with broad-spectrum antibiotic activity against multidrug-resistant bacteria that cause life-threatening infections.

Under the agreement, GARDP will provide up to U.S. $20 million to Bugworks in technical and financial support for the pharmaceutical and clinical co-development of BWC0977. In return, Bugworks has granted GARDP manufacturing and commercialisation rights for BWC0977 in 146 countries, almost all of which are low- or middle-income (LMICs).

BWC0977 has in vitro activity against a broad spectrum of pathogens that lead to serious hospital-acquired infections like pneumonia, bloodstream infections and complicated urinary tract infections.

Among these pathogens are WHO critical priority pathogens, carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae, for which few treatment options exist. According to the GRAM study, these two pathogens alone account for over one-fifth of deaths associated with antimicrobial resistance (AMR) in 2019. The study also shows that, in many countries around the world, over 80% of A. baumannii clinical isolates were carbapenem resistant.

“We are excited to work with Bugworks to make key investments at this critical stage in the development of compound BWC0977.Many compounds in the antibiotic pipeline lack innovative characteristics and fail to target priority pathogens. In contrast, BWC0977 stands out for its novelty and potential to address unmet public health needs,” said Manica Balasegaram, Executive Director of GARDP.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.